|
|
|
|
|
|
|
|
|
|
|
|
|
17.09.26 - 11:24
|
Viatris′ Wakix receives Japanese approval to treat OSAS and narcolepsy (PBR)
|
|
|
The approval covers patients with OSAS who continue to experience EDS while receiving treatment for airway obstruction. It also applies to narcolepsy with and without cataplexy, a condition
The post Viatris' Wakix receives Japanese approval to treat OSAS and narcolepsy appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.08.26 - 13:03
|
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease (GlobeNewswire EN)
|
|
|
NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is currently approved in the U.S., China, and Taiwan, with marketing authorization applications pending in other countries....
|
|
|
06.08.26 - 13:01
|
Viatris Reports Second-Quarter 2026 Financial Results (PR Newswire)
|
|
|
Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025 Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
